This content is intended for healthcare professionals in Europe, excluding the UK, only. Please confirm that you are a healthcare professional in Europe, excluding the UK.

Decline

This activity has been sponsored by Grifols, S.A. Grifols, S.A. provided financial support and has had input into the selection of the faculty and/or the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchNEUROLOGY.

Alzheimer's Disease & Dementia View Time: 37 mins

touchSYMPOSIUM HIGHLIGHTS Plasma exchange plus albumin in the field of Alzheimer’s disease: the AMBAR approach

Watch leading experts present data from the AMBAR study and discuss the role of therapeutic plasma exchange in the field of Alzheimer’s disease.

  • Part 1: Symposium Presentations
Introduction
Plasma exchange in neurology: a long experience of a safe procedure
AMBAR: a multi-mechanism approach for AD
AMBAR: primary results
An introduction to the AMBAR centre, Barcelona
 
Overview

In this sponsored symposium, leading experts discuss plasma exchange plus albumin in the field of Alzheimer’s disease and review the latest clinical data.

About Faculty

Prof. Mercè Boada
Ace Alzheimer Center Barcelona – Universitat Internacional de Catalunya, Barcelona, Spain

Mercè Boada is a neurologist, founder, and medical director of ACE Alzheimer Center Barcelona. She is a distinguished professor at the Universitat Internacional de Catalunya and member of the Executive Committee of the European Alzheimer’s disease Consortium.

Prof. Miquel Lozano
Department of Hemotherapy and Hemostasis, the Hospital Clínic in Barcelona, University of Barcelona, Barcelona, Spain

Miquel Lozano is a haematologist and Chief of Hemotherapy Section at the Hospital Clínic in Barcelona. Prof. Lozano is also associate professor of Medicine at the Universitat in Barcelona, President of the European Society of Hemapheresis, and European Vicepresident of the World Apheresis Association.

Dr Montserrat Costa
Director of Plasma Proteins Research, Grifols, Barcelona, Spain

Montserrat Costa is a chemist, and received her PhD in Cellular Biology at the Autonomous University of Barcelona. She is the Director of Plasma Proteins Research and responsible for the non-clinical research on Alzheimer’s disease at Grifols.

Prof. Javier Olazarián
Neurology Service, Gregorio Marañón University Hospital, and the Memory Disorders Clinic, HM University Hospital, Madrid, Spain

Javier Olazarán is a neurologist working at the University Hospital Gregorio Marañón in Madrid. He is also Director of Research Unit and Memory Treatment, HM University Hospital, and Neurology Professor at the Medicine School of the Universidad Complutense in Madrid. Dr Olazarán has been an investigator of the AMBAR trial at his hospital.

Disclosures:
Prof. Mercè Boada discloses: Consultant fees: Grifols, Araclon Biotech, Roche, Biogen, Lilly, Merck, Zambon. Advisory boards: Grifols, Roche, Lilly, Araclon Biotech, Merck, Zambon, Biogen, Novo-Nordisk, Bioiberica, Eisai, Servier, Schwabe Pharma. Lectures: Roche, Biogen, Grifols, Nutricia, Araclon Biotech, Servier. Funding sources: Life Molecular Imaging, Bioiberica. Grants: CIBERNED Instituto de Salud Carlos III (ISCIII), the EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975, from EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100, from PREADAPT project. Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097, and from grants PI13/02434, PI16/01861 BA19/00020, and PI19/01301, European Marie Sklodowska Curie. Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”), by Fundación bancaria “La Caixa” and Grífols SA (GR@ACE project).

Prof. Miquel Lozano discloses: Consulting fees: Grifols. Lectures: Grifols. Research Sources: Terumo BCT, and Maco-Pharma. ML serves as Editor-in-Chief of Vox Sanguinis and as President of European Society for Hemapheresis.

Dr Montserrat Costa discloses: Employee of Grifols.

Prof. Javier Olazarán discloses: Personal compensation (scientific advisory board or speaker): Zambon, Grifols, Nutricia, and Bial. Research support: Nutricia

  • Part 2: Expert Interview
Leave Feedback
Prof. Mercè Boada
Watch Time: 06:18
Ace Alzheimer Center Barcelona – Universitat Internacional de Catalunya, Barcelona, Spain

Prof. Mercè Boada discusses her experience of therapeutic plasma exchange in the field of Alzheimer’s disease: the AMBAR approach

 
Leave Feedback
Interview Questions

In this interview, we asked Prof. Mercè Boada the following questions:

  • As one of the primary investigators of the AMBAR Clinical program, and Medical Director of the ACE Alzheimer Center Barcelona, what is your impression of the patient's experience of plasma exchange?
  • Can you describe any practical learnings from the clinical trial that you now apply in the AMBAR Center?
  • How would you describe the typical patient profile of a candidate for the AMBAR procedure?
About Prof. Mercè Boada

Mercè Boada is a neurologist, founder, and medical director of ACE Alzheimer Center Barcelona. She is a distinguished professor at the Universitat Internacional de Catalunya and member of the Executive Committee of the European Alzheimer’s disease Consortium.

Prof. Mercè Boada discloses: Consultant fees: Grifols, Araclon Biotech, Roche, Biogen, Lilly, Merck, Zambon. Advisory boards: Grifols, Roche, Lilly, Araclon Biotech, Merck, Zambon, Biogen, Novo-Nordisk, Bioiberica, Eisai, Servier, Schwabe Pharma. Lectures: Roche, Biogen, Grifols, Nutricia, Araclon Biotech, Servier. Funding sources: Life Molecular Imaging, Bioiberica. Grants: CIBERNED Instituto de Salud Carlos III (ISCIII), the EU/EFPIA Innovative Medicines Initiative Joint Undertaking, ADAPTED Grant No. 115975, from EXIT project, EU Euronanomed3 Program JCT2017 Grant No. AC17/00100, from PREADAPT project. Joint Program for Neurodegenerative Diseases (JPND) Grant No. AC19/00097, and from grants PI13/02434, PI16/01861 BA19/00020, and PI19/01301, European Marie Sklodowska Curie. Acción Estratégica en Salud, integrated in the Spanish National RCDCI Plan and financed by Instituto de Salud Carlos III (ISCIII)- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER – “Una manera de Hacer Europa”), by Fundación bancaria “La Caixa” and Grífols SA (GR@ACE project).

Please Select A Video:
Leave Feedback
Overview & Learning Objectives
Overview

Therapeutic plasma exchange is widely used for the treatment of various neurological, autoimmune and inflammatory conditions.1,2 In this sponsored Symposium, presented at the 7th Congress of the European Academy of Neurology (EAN) on 21st June 2021, four leading experts discuss the latest clinical data on the use of therapeutic plasma exchange in the field of AD.3

Learning Objectives

After watching this activity, participants should be better able to:

  • Discuss the current treatment landscape in Alzheimer’s disease.
  • Describe the rationale behind the use of therapeutic plasma exchange in Alzheimer’s disease.
  • Review the results of the AMBAR study.
References
References
  1. Costa M, Paez A. Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management. Transfus Apher Sci. 2021;60:103164.
  2. Padmanabhan A, Connelly-Smith L, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue. J Clin Apher. 2019;34:171–354.
  3. Boada M, Lopez OL, Olazaran J, et al. A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study. Alzheimers Dement. 2020;16:1412–25.
Downloads

View and download resources from this activity to support your learning and share with your HCP colleagues

Feedback Close
Feedback

Please provide feedback for this touchSYMPOSIUM HIGHLIGHTS on the following
(scale of 1-5 where 1=strongly disagree and 5=strongly agree):

Feedback Close
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72